Collegium Pharmaceutical (NASDAQ: COLL) is one of 115 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its rivals? We will compare Collegium Pharmaceutical to similar businesses based on the strength of its risk, earnings, analyst recommendations, profitability, valuation, dividends and institutional ownership.

Volatility & Risk

Collegium Pharmaceutical has a beta of -0.13, indicating that its stock price is 113% less volatile than the S&P 500. Comparatively, Collegium Pharmaceutical’s rivals have a beta of 34.26, indicating that their average stock price is 3,326% more volatile than the S&P 500.

Profitability

This table compares Collegium Pharmaceutical and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Collegium Pharmaceutical -1,319.39% -93.73% -74.81%
Collegium Pharmaceutical Competitors -2,902.57% -69.29% -9.41%

Valuation & Earnings

This table compares Collegium Pharmaceutical and its rivals gross revenue, earnings per share (EPS) and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
Collegium Pharmaceutical $1.71 million -$94.17 million -2.68
Collegium Pharmaceutical Competitors $8.39 billion $1.12 billion 52.30

Collegium Pharmaceutical’s rivals have higher revenue and earnings than Collegium Pharmaceutical. Collegium Pharmaceutical is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Collegium Pharmaceutical and its rivals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Collegium Pharmaceutical 0 0 5 0 3.00
Collegium Pharmaceutical Competitors 844 3753 6748 185 2.54

Collegium Pharmaceutical presently has a consensus target price of $20.00, suggesting a potential upside of 103.67%. As a group, “Pharmaceuticals” companies have a potential upside of 35.07%. Given Collegium Pharmaceutical’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Collegium Pharmaceutical is more favorable than its rivals.

Insider & Institutional Ownership

83.1% of Collegium Pharmaceutical shares are owned by institutional investors. Comparatively, 43.0% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 25.8% of Collegium Pharmaceutical shares are owned by company insiders. Comparatively, 11.8% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting. Xtampza ER is designed to provide adequate pain control while maintaining its extended-release drug release profile after being subjected to common methods of abuse and accidental misuse. ONSOLIS is a Transmucosal Immediate-Release Fentanyl (TIRF) film indicated for the management of breakthrough pain in cancer patients (BTPc), 18 years of age and older, who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.

Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.